A unique opportunity

HaemaLogiX focus is the development and commercialisation of novel immuno-oncology and immune-therapies. HaemaLogiX acquired the business and assets of Immune System Therapeutics and is embarking on a program of several inter-related research and clincial development projects that will validate the antigen targets and products. We have a unique opportunity to develop effective treatments that improve the quality of life of patients suffering from blood cancers and autoimmune diseases.

Two novel drug targets - Kappa Myeloma Antigen (KMA) and Lambda Myeloma Antigen (LMA), have been identified on the surface of human blood cancer and autoimmune cells. These targets are highly specific to abnormal B-cells and have been identified in blood cancers such as multiple myeloma (MM), lymphoma and Waldenstroms macroglobulinemia.

Read More